Navigation Links
Beckman Coulter Announces First Quarter 2009 Results
Date:4/28/2009

ly cash dividend payable on March 6, 2009 to all stockholders of record on February 20, 2009. This payout represents the 79th consecutive, quarterly payout of dividends.
  • Entered into a definitive agreement to purchase the lab-based diagnostics business of Olympus Corporation for approximately $780 million. The acquisition will significantly extend Beckman Coulter's geographic reach and Chemistry depth. The transaction is expected to close in the third quarter of 2009 and be substantially accretive to non-GAAP earnings in 2010.
  • Acquired Clinical Data's Cogenics division, a global leader in outsourced genomics services, for approximately $17 million, significantly extending the range of services and geographic reach of the company's Agencourt sequencing business.

  • Full Year Outlook

    "We are affirming our outlook, despite the potential for lower cash instrument sales in 2009. Solid constant currency recurring revenue gains are expected to continue with full year growth of 6% to 7%. As a result, on a constant currency basis, our 2009 full year outlook for revenue growth remains at 4% to 6%, or flat on a reported basis," Garrett continued.

    "We remain committed to customer satisfaction, careful expense management and delivering on our earnings goals. Operating margin, now including normal hedging activities, is anticipated to be between 12.6% and 12.9%, after absorbing the effects of a stronger dollar and a $25 million increase in pension expense. Adjusted non-operating expense, now excluding normal hedging activities, should be around $62 million. Based on an estimated tax rate of 26% to 27%, our outlook for adjusted earnings per fully diluted share remains unchanged at $3.71 to $3.91 (including $0.14 additional non-cash interest expense associated with the convertible debt accounting change). Capital expenditures are expected to be $350 to $375 m
    '/>"/>

    SOURCE Beckman Coulter, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

    Related biology technology :

    1. Beckman Coulter Announces First Quarter 2009 Earnings to be Released on Tuesday, April 28, 2009, After Market Closes
    2. Beckman Coulter to Webcast Annual Stockholders Meeting
    3. Beckman Coulter to Acquire Lab-Based Diagnostics Business From Olympus Corporation
    4. Beckman Coulter Announces Fourth Quarter and Full Year 2008 Results; Earnings Outlook Achieved on Strong Fundamentals
    5. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
    6. Beckman Coulter Announces Fourth Quarter 2008 Earnings to be Released on Monday, February 9, 2009, After Market Closes
    7. Beckman Coulter to Present at the 27th Annual J.P. Morgan Healthcare Conference
    8. Beckman Coulter to Host Annual Business Review
    9. Beckman Coulter to Present at Upcoming Healthcare Conferences
    10. Beckman Coulter to Present at the Lazard Capital Markets 5th Annual Healthcare Conference
    11. Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/23/2014)... TEL AVIV, Israel , July 23, 2014 ... Ltd ., a portfolio company of Trendlines ... with one of Israel,s ... (Logo: http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines ... from plant pulp waste, with additional nanoparticles to ...
    (Date:7/23/2014)... , July 23, 2014 regulated information -- UCB ... and development pipeline with positive topline results from ... . This study was designed to evaluate the efficacy ... 200 mg/day, without titration) compared to placebo, as ... partial-onset seizures, not fully controlled despite treatment with ...
    (Date:7/23/2014)... PARK, Calif. , July 23, 2014  Sofinnova ... investment firm, today announced the closing of Sofinnova Venture ... million and in excess of the initial fund target ... helping entrepreneurs build successful biotechnology companies. Consistent with recent ... with promising later stage clinical programs, along with select ...
    (Date:7/23/2014)... July 23, 2014 OncLive® is ... Center has joined its Strategic Alliance Partnership program. ... Partnership program, UNC Lineberger will have the opportunity ... awareness of its cutting-edge research initiatives, community-directed cancer ... Lineberger will work with OncLive to educate their ...
    Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
    ... , CORALVILLE, Iowa, Nov. 17 Vivakor, Inc. (OTC ... approved a dividend of shares of common stock of HealthAmerica, ... of the outstanding common stock. Each Vivakor shareholder will ... for each share of Vivakor common stock beneficially owned on ...
    ... Neuralstem, Inc. (NYSE Amex: CUR ) today provided a financial ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO ) , ... loss of $5,096,983, or $0.15 per share, compared with a net ... period. The increase was due to a non-cash charge related to ...
    ... LEIDEN, The Netherlands, November 17 ... with Actelion Pharmaceuticals Ltd,Erasmus Medical Centre and Maastricht ... hypertension (high blood pressure) and associated vascular,complications such as ... novel action mechanisms, new drugs may be discovered with,the ...
    Cached Biology Technology:Vivakor, Inc. Announces Stock Dividend 2Vivakor, Inc. Announces Stock Dividend 3Vivakor, Inc. Announces Stock Dividend 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications 2
    (Date:7/23/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
    (Date:7/23/2014)... and blood-brain barrier damage appear after cerebral ... Matrix metalloproteinase-9 is able to degrade the ... cerebral blood vessels and to mediate extracellular ... colleagues from the First Affiliated Hospital of ... induced cerebral infarction in stroke-prone spontaneously hypertensive ...
    (Date:7/23/2014)... Scientists with the NH Agricultural Experiment Station are working ... after new research based on genetic monitoring has found ... New England have become more isolated and seen a ... endangered New England cottontail is now is at risk ... Agricultural Experiment Station researchers at the University of New ...
    Breaking Biology News(10 mins):Nano-sized chip "sniffs out" explosives far better than trained dogs 2UNH NHAES researchers work to save endangered New England cottontail 2UNH NHAES researchers work to save endangered New England cottontail 3
    ... The ubiquitous and usually harmless E. coli bacterium, which ... has more than 1,000 of them involved in metabolism ... genes would theoretically be capable of generating a huge ... report in the Dec. 27 issue of Proceedings of ...
    ... medical doctor. Yet he is seen as a hero by ... was diagnosed with terminal lung cancer. , "In 2000 he ... months to live," said Pardini, a professor of biochemistry and ... University of Nevada, Reno. "But five years later, he ...
    ... great challenges for treating Parkinson's diseases and other neurodegenerative disorders ... , The brain is a complex organ with many different ... a protective barrier erected by blood vessels and glial cells ... the delivery of most drugs from the bloodstream. , But ...
    Cached Biology News:How E. coli bacterium generates simplicity from complexity 2How E. coli bacterium generates simplicity from complexity 3The nude mouse tale: Omega-3 fats save the life of a terminal cancer patient 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 2Engineered Stem Cells Show Promise For Sneaking Drugs Into The Brain 3
    ... are rigid macroporous hydrophilic media. The rigid ... moderate pressures, while the macroporous beads enhance ... matrix reduces nonspecific binding. Macro-Prep High Q ... with very high flow rates and resolution. ...
    ... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
    ... The IDS 25-Hydroxy Vitamin D kit ... quantitative determination of 25-hydroxyvitamin D (25-OH ... human serum or plasma. Our patented ... of solvent precipitation and centrifugation and ...
    ... A multi-purpose, high gel-strength agarose suitable for ... from conventional constant field to Pulsed Field ... gel strength and exclusion limits, Multi ABgarose ... reduced running times. This in turn means ...
    Biology Products: